ArticleDiabetologia2020

Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort.

Barnabas Gellen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.